Weight loss drugs like Ozempic and Wegovy are changing cancer survivorship conversations. But are GLP-1 medications actually safe after cancer treatment? In this video, medical oncologist Dr. Francisco J. Esteva explains what the real data shows about obesity drugs, cancer recurrence risk, metabolic health, and long-term survival.
You’ll learn:
• Why early animal studies triggered cancer fears
• What researchers mean by “confounding” in obesity drug studies
• Why obesity and metabolic syndrome can worsen cancer outcomes
• When GLP-1 drugs may make sense after cancer treatment
• Which cancer survivors should avoid these medications entirely
• Why muscle loss and sarcopenia matter during weight loss
This video also walks through real-world clinical scenarios involving breast cancer survivors, including hormone receptor-positive and triple-negative breast cancer, and explains the “risk versus risk” framework oncologists use when making these decisions.
CHAPTERS:
00:00 Introduction
00:44 Why GLP-1 Fear Started
01:37 Confounding Explained
02:42 Risk vs Risk
03:02 Cancer Biology
03:46 Treatment Timing
04:27 Metabolic Risk
05:13 Real Patient Stories
07:00 Muscle Loss Warning
07:29 Conclusion
🔔 Subscribe for evidence-based updates in breast cancer research, screening, and treatment.
ABOUT DR. ESTEVA:
Francisco J. Esteva, MD, PhD is Chief of Hematology and Medical Oncology at Lenox Hill Hospital in New York City and a breast cancer specialist with more than 25 years of experience in cancer research and clinical care. He has led over 100 clinical trials in breast cancer diagnostics and treatment.
⚠️ DISCLAIMER:
This video is for educational purposes only and does not constitute medical advice. Always consult your physician or healthcare team regarding your specific diagnosis, screening, or treatment plan. Views expressed are Dr. Esteva’s own and do not reflect those of his employer.
This video is not sponsored. Mentions of products, medications, or brands are for educational purposes only and do not imply endorsement. Advertisements, if any, are placed by YouTube and are not selected or endorsed by Dr. Esteva.
#BreastCancer #ozempic #cancertreatment #cancerawareness
source
Many cancer survivors are told to avoid Ozempic or Wegovy because of fear about cancer recurrence. But when doctors look closely at the data, the conversation becomes much more complicated.
In this video, I explain why obesity itself may sometimes be the bigger long-term threat, what the real studies show about GLP-1 drugs after cancer, and which patients should avoid these medications entirely.
💬 If you were a cancer survivor struggling with weight or diabetes, would you consider a GLP-1 medication?
I was on GLP1 for about year and now I’m just diagnosed with breast cancer, triple negative. I have no other health history…
Самый правильный совет – проконсультироваться со своим онкологом, так как все зависит от типа рака и других особенностей. Но если говорить о Седжаро, препарат действительно заслуживает внимания, проверенный и безопасный вариант. И не забывать, все только под контролем врача
🌏💗🙏🏻
Thank you! I was so concerns 😮
Can a breast cancer patient aged 64 who is currently cancer free, under followup for 2.5 years take multi vitamin medicine?